TRANSLATION FROM BENCH TO BEDSIDE: PET TRACERS FOR USE IN NEUROSCIENCE DRUG DEVELOPMENT

Eric D. Hostetler

Executive Director Translational Biomarkers Merck Research Laboratories

ASCPT March 23, 2018





Presentation Outline

- Strategies to improve clinical drug development: a role for PET
- Target engagement PET in neuroscience drug development
- PET: beyond target engagement






Presentation Outline

- Strategies to improve clinical drug development: a role for PET
- Target engagement PET in neuroscience drug development
- PET: beyond target engagement





Drug Development Success Rates The Need for Earlier Clinical Decisions



Calcoen D, et al. Nat Rev Drug Disc (2015) 14:161-162





Principles to Improve Phase II Outcomes Three Pillars of Survival

Pillar 1: Exposure at the target site of action

Public

٨

Pillar 2: Binding to the pharmacological target

Pillar 3: Expression of pharmacology

Hi

Exposure confidence	Pillar 1 and 2 Target exposure and target binding concur but no data to show relevant downstream pharmacology effect at site of action. Risk in relying only on exposure and binding; study design &	Pillar 1,2,3 Target exposure shown and concurs with target binding which results in expression of relevant downstream pharmacology effect at site of action. PKPD well established. Maximum confidence in translation of drug
	decision-making from clinical endpoint needs to be clear	exposure and pharmacology & of testing the mechanism Pillar 2 and 3
	None or partial Pillars Binding to target but no data to show relevant downstream pharmacology effect; exposure only in plasma, not at target site (e.g CNS). PKPD not well established. Serious concerns that mechanism will not be tested & clinical studies unlikely to be definitive	Binding to target shown but exposure only in plasma, not at target site (e.g local administration to target); data showing relevant downstream pharmacology effect. Reasonable risk being carried forward if confident that drug reaches target in humans & clinical endpoint relevant to site of action

Pharmacology confidence

"The highest level of confidence and direct evidence at the site of action that required levels of target binding were being achieved is most probably obtained from PK/PD studies of in vivo occupancy measurements with positron emission tomography (PET) or radiolabeled ligands."



Morgan P, et al. Drug Disc Today (2012) 17:419-424

Presentation Outline


- Strategies to improve clinical drug development: a role for PET
- Target engagement PET in neuroscience drug development
- PET: beyond target engagement





Neuroscience Biomarker Strategy PET tracers for Target Engagement/Dose Selection

NK1 PET Tracer binding in brain



Bergstrom et al, (2004), Biological Psychiatry, 55:1007-1012

MERCK

ENTING FOR LIFE



Substance P: NK₁ Receptor Antagonists

REDUCTION OF CISPLATIN-INDUCED EMESIS BY A SELECTIVE NEUROKININ-1-RECEPTOR ANTAGONIST


RUDOLPH M. NAVARI, M.D., RICK R. REINHARDT, M.D., PH.D., RICHARD J. GRALLA, M.D., MARK G. KRIS, M.D., PAUL J. HESKETH, M.D., ALI KHOJASTEH, M.D., HEDY KINDLER, M.D., THOMAS H. GROTE, M.D., KELLY PENDERGRASS, M.D., STEVEN M. GRUNBERG, M.D., ALEXANDRA D. CARIDES, PH.D., AND BARRY J. GERTZ, M.D., PH.D., FOR THE L-754,030 ANTIEMETIC TRIALS GROUP*

The New England Journal of Medicine 190 · January 21, 1999

11 SEPTEMBER 1998 VOL 281 SCIENCE www.sciencemag.org

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Mark S. Kramer,* Neal Cutler, John Feighner, Ram Shrivastava, John Carman, John J. Sramek, Scott A. Reines, Guanghan Liu, Duane Snavely, Edwina Wyatt-Knowles, Jeffrey J. Hale, Sander G. Mills. Malcolm MacCoss. Christopher I. Swain.







Public

Substance P: NK₁ Receptor Antagonists Phase Ila Study for Depression


Public



Aprepitant - Clinical PET Occupancy Study Target Engagement Guiding Dose Selection



Cisplatin chemotherapy followed by Aprepitant




Chawla et al, (2003), Cancer, 97:2290-300





PET Target Engagement Increasing Patient Options


Public



 PET shows bioequivalence, supporting registration of alternate dosage form without need for clinical efficacy trials



PET Target Engagement *Definitive proof of concept: NPY5-R antagonism for obesity*




- NPY5 implicated in weight loss but effect is clinically insufficient
- PET data ensures mechanism was adequately tested





PET Target Engagement Early No Go Decision: Depression

~ 35% SERT occupancy



Meyer et al. Am. J. Psychiatry (2004) 161: 826.

- All SSRIs require 80% SERT occupancy
- Novel Rx candidate only reaches 55% occupancy @ Cmax
- M&S predicts high multiple daily doses needed to achieve target occupancy
- Early No Go decision




Public

High

Low

PET Target Engagement Proof of Mechanism: CGRP-R and Migraine



Hostetler et al. JPET (2013) 347:478-486.


[¹¹C]MK-4232 and telcagepant

- Unknown if anti-migraine efficacy of telcagepant was driven by peripheral or central target engagement
- PET studies: negligible occupancy of central CGRP receptors at efficacious dose of CGRP-R antagonist telcagepant
- Mechanism of action is peripheral focuses drug discovery program






Neuroscience Biomarker Strategy Optimal design of PET occupancy studies





Public

PET Target Engagement Monkey as a Predictive Model for Human







PET Target Engagement Impact on decision-making

- Human dose prediction
- Go/No Go to Phase Ib/2
- Dose selection for POC study
- Maximize safety margins
- Confident testing of mechanism
- Demonstration of phamacodynamic bioequivalence
- Understanding mechanism of action






Presentation Outline

- Strategies to improve clinical drug development: a role for PET
- Target engagement PET in neuroscience drug development
- PET: beyond target engagement





Beyond Target Engagement Patient Identification & Disease Progression Measure



Biomarker strategies to enable smaller, shorter POC trials are desperately needed






Beyond Target Engagement Amyloid PET: Patient Identification & Disease Progression Measure

Amyloid PET Biomarker Strategy

Enroll amyloid plaque+ patients Longitudinal Studies

Evaluate changes in plaque burden

Aducanumab: Amyloid-β fibril mAb




Sevigny J, et al. Nature (2016) 537:50-56





Beyond Target Engagement Tau PET: Patient Identification & Disease Progression Measure




Public




Beyond Target Engagement *Biomarker Needs for Neurodegenerative Diseases*

Imaging Synaptic Density (SV2A) with [¹¹C]UCB-J



Finnema SJ et al. Sci Transl Med (2016) 8:348

Imaging Neuroinflammation (TSPO) in AD with [¹¹C]PBR-28







Kreisl WC et al. (2016) Neurobiol Aging 44:53-61



- The challenges of drug development require earlier and better clinical decision-making
- Application of PET tracers has improved the speed, quality, and confidence of early clinical decision-making for neuroscience drug development





THANK YOU!





What Makes a Good CNS PET Tracer?

- NOT the radiolabeled version of a drug (in general)
- Relative to therapeutic candidates, PET tracers typically require:
 - Higher affinity
 - Lower lipophilicity
 - Better diffusion across blood-brain barrier
- Robust, reliable <u>radiochemistry</u> is a must
- Adequate <u>selectivity</u> for imaging
- Rigorous method for <u>quantification</u> of PET data is critical



